1005960-87-1Relevant academic research and scientific papers
Discovery of MK-4409, a novel oxazole FAAH inhibitor for the treatment of inflammatory and neuropathic pain
Chobanian, Harry R.,Guo, Yan,Liu, Ping,Chioda, Marc D.,Fung, Selena,Lanza, Thomas J.,Chang, Linda,Bakshi, Raman K.,Dellureficio, James P.,Hong, Qingmei,McLaughlin, Mark,Belyk, Kevin M.,Krska, Shane W.,Makarewicz, Amanda K.,Martel, Elliot J.,Leone, Joseph F.,Frey, Lisa,Karanam, Bindhu,Madeira, Maria,Alvaro, Raul,Shuman, Joyce,Salituro, Gino,Terebetski, Jenna L.,Jochnowitz, Nina,Mistry, Shruti,McGowan, Erin,Hajdu, Richard,Rosenbach, Mark,Abbadie, Catherine,Alexander, Jessica P.,Shiao, Lin-Lin,Sullivan, Kathleen M.,Nargund, Ravi P.,Wyvratt, Matthew J.,Lin, Linus S.,Devita, Robert J.
, p. 717 - 721 (2014/07/07)
We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency,
